3rd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$1,200,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; HR 749-Lower Drugs Through Competition Act; and FDA Reauthorization Act of 2017.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
SHANNON DZUBIN —
ROBERT FALB —
DOLLY A JUDGE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office

Bills named: H.R. 1628 (115th), S. 637 (115th), H.R. 2051 (115th), S. 469 (115th), H.R. 749 (115th), S. 771 (115th)

Taxation/Internal Revenue Code TAX

Corporate tax reform proposals including proposed boarder adjustment tax.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SHANNON DZUBIN —
DOLLY A JUDGE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.